Hepion Pharmaceuticals (Hepion Pharmaceuticals) Interest Expense : $-0.01 Mil (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Hepion Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Hepion Pharmaceuticals's interest expense for the three months ended in Dec. 2023 was $ -0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.01 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Hepion Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $ -7.22 Mil. Hepion Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $ -0.00 Mil. Hepion Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Hepion Pharmaceuticals Interest Expense Historical Data

The historical data trend for Hepion Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hepion Pharmaceuticals Interest Expense Chart

Hepion Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.56

-0.03

-0.01

Hepion Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Hepion Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

Hepion Pharmaceuticals (NAS:HEPA) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Hepion Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $-0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-7.22 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $0.09 Mil.

Hepion Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Hepion Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Hepion Pharmaceuticals (Hepion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (NAS:HEPA) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

399 Thornall Street, First Floor, Edison, NJ, USA, 08837

Website

https://www.hepionpharma.com

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Executives

Peter Wijngaard	director	8 SYLVAN WAY, PARSIPPANY NJ 07054
Robert T Foster	officer: Chief Scientific Officer	C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Kaouthar Lbiati	director	399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Anand Reddi	director	399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
John T Cavan	officer: Chief Financial Officer	C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022
John P Brancaccio	director	C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob	director, officer: CEO and President
Donald E Garlikov	10 percent owner	41 S. HIGH STREET, SUITE 3400, COLUMBUS OH 43215
Tamar D Howson	director
Thomas Phd Adams	director
Gabriel Cerrone	10 percent owner	VIA SANT' ANDREA 18, MILAN L6 20121
John Z Sullivan-bolyai	officer: Chief Medical Officer	C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, 1ST FLOOR, EDISON NJ 08837
James Sapirstein	director, officer: Chief Executive Officer	1517 SAN JACINTO, HOUSTON TX 77002
Arnold Lippa	director	C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
William Karl Hornung	officer: Chief Financial Officer	C/O CONTRAVIR PHARMACEUTICALS, INC., 420 LEXINGTON AVE., SUITE 300, NEW YORK NY 10170